Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finasteride safety in FTM transgender patients with androgenetic alopecia during testosterone therapy
jRCTs061210040Completed
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of finasteride in androgenetic alopecia (AGA). Primary endpoint: Primary: Safety and treatment continuation at 3 months. Started Jan 2022; status: completed.
02
Drugs
finasteride
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on jRCTs061210040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061210040.